Allogene Therapeutics Inc
NASDAQ:ALLO
Intrinsic Value
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatmen... [ Read More ]
The intrinsic value of one
ALLO
stock under the Base Case scenario is
9.22
USD.
Compared to the current market price of 3.18 USD,
Allogene Therapeutics Inc
is
Undervalued by 66%.
ALLO's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
ALLO or that its price is influenced by factors unrelated to fundamentals.
Allogene Therapeutics Inc's market capitalization is 536.3m USD.
ALLO stock price is 3.18 USD.
ALLO stock price (3.18 USD) is 66% less than its Intrinsic Value (9.22 USD).
ALLO. Open DCF Valuation
ALLO has upside potential of 211% compared to the average analyst price target.
Open Wall St Estimates
ALLO's Revenue has dropped by 60% over the past 12 months.
ALLO's ROE (Return on Equity) has significantly decreased in the last 3 years from -27% to -56%, and is approaching profitability.
ALLO's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -72% to -133%, and is approaching profitability.
ALLO has negative Operating Income for the last twelve months.
ALLO has negative Net Income for the last twelve months.
ALLO's ROE (Return on Equity) for the past 12 months is negative and is equal to -56%.
ALLO's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -133%.
ALLO's Revenue is forecast to grow at a rate of 706% per year over the next 3 years.
ALLO has negative Free Cash Flow for the last twelve months.
ALLO has negative three-year average ROE (Return on Equity): -37%. The company is not efficient at transforming stockholders' equity into net income.
ALLO has negative three-year average ROIC (Return on Invested Capital): -80%. The company is not efficient at using invested capital to generate operating income.
ALLO's short-term assets (459m USD) exceed its short-term liabilties (37m USD).
ALLO's long-term assets (643m USD) exceed its long-term liabilties (131m USD).
ALLO's D/E (Debt to Equity) is very low and is equal to 0.
ALLO's Altman Z-Score is very low and is equal to -2.58.
Valuation Backtest
Allogene Therapeutics Inc
Run backtest to discover the historical profit from buying and selling
ALLO
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Allogene Therapeutics Inc
Balance Sheet Decomposition
Allogene Therapeutics Inc
| Current Assets | 459.1m |
| Cash & Short-Term Investments | 448.7m |
| Other Current Assets | 10.4m |
| Non-Current Assets | 183.7m |
| Long-Term Investments | 3.6m |
| PP&E | 163.2m |
| Other Non-Current Assets | 16.9m |
| Current Liabilities | 37.1m |
| Accounts Payable | 5.9m |
| Accrued Liabilities | 31.1m |
| Other Current Liabilities | 86k |
| Non-Current Liabilities | 93.5m |
| Other Non-Current Liabilities | 93.5m |
Earnings Waterfall
Allogene Therapeutics Inc
|
Revenue
|
95k
USD
|
|
Operating Expenses
|
-314.6m
USD
|
|
Operating Income
|
-314.5m
USD
|
|
Other Expenses
|
-12.8m
USD
|
|
Net Income
|
-327.3m
USD
|
Free Cash Flow Analysis
Allogene Therapeutics Inc
ALLO Profitability Score
Profitability Due Diligence
Allogene Therapeutics Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Allogene Therapeutics Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
ALLO Solvency Score
Solvency Due Diligence
Allogene Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Allogene Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALLO Price Targets Summary
Allogene Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
ALLO
is 9.88 USD
with a low forecast of 4.44 USD and a high forecast of 17.85 USD.
Ownership
ALLO Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ALLO Price
Allogene Therapeutics Inc
| Average Annual Return | -27.39% |
| Standard Deviation of Annual Returns | 29.26% |
| Max Drawdown | -96% |
| Market Capitalization | 536.3m USD |
| Shares Outstanding | 169 092 000 |
| Percentage of Shares Shorted | 26.6% |
Company Profile
Allogene Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 310 full-time employees. The company went IPO on 2018-10-11. The firm is focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is engaged in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced T cell manufacturing technologies. Its advanced product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. The company is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma (ccRCC), and other blood cancers and solid tumors. Its lead product candidates include ALLO-501, ALLO-501A, ALLO-715, ALLO-715 plus nirogacestat, ALLO-605, ALLO-316, and ALLO-647.
Contact
IPO
Employees
Officers
The intrinsic value of one
ALLO
stock under the Base Case scenario is
9.22
USD.
Compared to the current market price of 3.18 USD,
Allogene Therapeutics Inc
is
Undervalued by 66%.
You don't have any saved screeners yet
